Variables | Case | Training cohort | P-value | Case | Validation cohort | P-value | ||
---|---|---|---|---|---|---|---|---|
Low expression | High expression | Low expression | High expression | |||||
Age | 102 | 68 | 79 | 53 | ||||
≤60a | 100 | 65 (50.9%) | 35 (49.1%) | 78 | 51 (54.5%) | 27 (45.5%) | ||
>60 | 70 | 37 (58.1%) | 33 (41.9%) | 0.112 | 54 | 28 (53.5%) | 26 (46.5%) | 0.119 |
Gender | ||||||||
Male | 109 | 64 (50.0%) | 45 (50.0%) | 88 | 51 (50.0%) | 37 (50.0%) | ||
Female | 61 | 38 (63.3%) | 23 (36.7%) | 0.648 | 44 | 28 (63.3%) | 16 (36.7%) | 0.53 |
Tumor grade | ||||||||
G1 | 56 | 39 (42.1%) | 17 (57.8%) | 38 | 23 (65.8%) | 15 (34.2%) | ||
G2 + 3 | 114 | 63 (61.7%) | 51 (38.3%) | 0.072 | 94 | 56 (46.7%) | 38 (53.3%) | 0.92 |
Tumor size(cm) | ||||||||
≤ 5b | 91 | 59 (51.0%) | 32 (49.0%) | 97 | 62 (53.1%) | 35 (46.9%) | ||
>5 | 79 | 43 (57.1%) | 36 (42.9%) | 0.167 | 35 | 17 (55.1%) | 18 (44.9%) | 0.112 |
T status | ||||||||
T1/2 | 37 | 25 (54.2%) | 12 (45.8%) | 44 | 31 (50.0%) | 13 (50.0%) | ||
T3/4 | 133 | 77 (54.1%) | 56 (45.9%) | 0.288 | 88 | 48 (55.4%) | 40 (44.6%) | 0.079 |
N status | ||||||||
N0 | 58 | 43 (34.5%) | 15 (65.5%) | 61 | 43 (72.4%) | 18 (27.6%) | ||
N1/2 | 112 | 59 (62.3%) | 53 (37.7%) | 0.007* | 71 | 36 (46.4%) | 35 (53.6%) | 0.021* |
Clinical stage | ||||||||
I + II | 69 | 50 (37.8%) | 19 (62.2%) | 70 | 49 (67.6%) | 21 (32.4%) | ||
III | 101 | 52 (63.9%) | 49 (36.1%) | 0.006* | 62 | 30 (45.9%) | 32 (54.1%) | 0.011* |